Archive | Biopharmaceuticals

Rayno Life Science Mid-day Movers: AMRI, ASTX, CPHD, ILMN, REGN

buy cheapest Deltasone and Deltasone Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany Molecular (AMRI $4.21) broke through to new highs up 43% YTD. […]

Continue Reading 0

Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally

go to link A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on favorable Phase 2 results with their antiviral drug GS-5885 in combination with ribavirin. […]

Continue Reading 0

Rayno Life Science: Biotechnology Sector Should Find Support Today

http://qualityfirstcontractor.com/wp-json/oembed/1.0// Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and re-balancing in anticipation for a Q4 rally : The IBB (130.82) is up 1.88%. The XBI is up 2.37%. MO stocks are […]

Continue Reading 0

Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More

Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with the overall sector up 40%. Despite recent media coverage of […]

Continue Reading 0

NASDAQ Correction Hits Biotechnology Stocks: Update 1 10/24

Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and  Gilead (GILD $68.85) up 6%. Biogen Idec earnings are due tomorrow. See summary below of 2012 […]

Continue Reading 0

Rayno Life Science Portfolios: Biotechnology Stocks Should Outperform in Q4

Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The Company is developing clinical stage therapeutics to treat chronic liver diseases. BofA MerrillLynch is acting as sole book running manager with […]

Continue Reading 0

Rayno Life Science Portfolio Biopharmaceuticals: ALXN, GILD, REGN, SGEN

Biotechnology Sector Continues Amazing Bull Run Up 40% YTD The Rayno Life Science Portfolio had nice gains today with 1% + moves from Biogen-Idec (BIIB) and Gilead Sciences (GILD) and with our bellwether ETF (IBB) eking out a 0.5% gain at its 52 week high. Since the bull market began in February 2009 several stocks […]

Continue Reading 0

Who Knows About the Bull Market in Biotech Stocks?

Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip stocks”; the other from an astute investor telling a […]

Continue Reading 0

NASDAQ Slips Down 0.4% But Biotech Sector Hits New Highs

The ETF IBB (142.62) hit an all time high today and is up 36.6% YTD. The low for IBB over two years was August 19, 2011 at $88.50. Our mid-cap biopharma index is up 0.8% with big winners in JAZZ ($54.65) and Exelixis (EXEL $5.40) and Medivation (MDVN $106.27). Diagnostics and tools got some M&A […]

Continue Reading 0

Biotechnology Does Create Jobs and MASS Effort pays Off

The MASS Biotechnology industry has crossed $6B as a 25 year effort beginning in 1985 with the MASS Biotechnology Council. Several major biotechnology companies were created around this time such as Biogen(BIIB)  and Vertex (VRTX) as well as major venture capital firms who invested $1B in 2011 and $8B since 2002. Several major pharmaceutical firms […]

Continue Reading 0